Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EPS (Basic) (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed EPS (Basic) for 11 consecutive years, with -$1.77 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 112.06% to -$1.77 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.66 through Dec 2025, up 177.65% year-over-year, with the annual reading at $0.64 for FY2025, 96.05% down from the prior year.
  • EPS (Basic) hit -$1.77 in Q4 2025 for Seres Therapeutics, down from $0.94 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $14.68 in Q4 2024 to a low of -$28.49 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$1.61 across 5 years, with a median of -$0.54 in 2022.
  • Biggest five-year swings in EPS (Basic): soared 305.56% in 2021 and later crashed 5175.93% in 2023.
  • Year by year, EPS (Basic) stood at -$0.55 in 2021, then grew by 1.82% to -$0.54 in 2022, then plummeted by 5175.93% to -$28.49 in 2023, then soared by 151.53% to $14.68 in 2024, then plummeted by 112.06% to -$1.77 in 2025.
  • Business Quant data shows EPS (Basic) for MCRB at -$1.77 in Q4 2025, $0.94 in Q3 2025, and -$2.27 in Q2 2025.